Compound class:
Synthetic organic
Comment: CIAC001 is a cannabidiol (CBD) analogue [1]. Its molecular target is reported as pyruvate kinase M2 (PKM2). CIAC001 is hypothesised to stabilise PKM2 tetramers within the cytosol, which reduces monomer translocation to the nucleus and thus attenuates neuronal inflammation. This mechanism is proposed as a therapeutic strategy to treat opioid addiction, by targeting opioid-caused neuroinflammation.
|
|
Bioactivity Comments |
CIAC001 dose-dependently inhibits the production of pro-inflammatoy mediators (IL-1β, TNFα, IL-6) by activated microglia. |